

Literaturverzeichnis

1. Tatoulis, J., B.F. Buxton, and J.A. Fuller, *Patencies of 2127 arterial to coronary conduits over 15 years*. Ann Thorac Surg, 2004. **77**(1): p. 93-101.
2. Tatoulis, J., B.F. Buxton, and J.A. Fuller, *The radial artery in coronary re-operations*. Eur J Cardiothorac Surg, 2001. **19**(3): p. 266-72; discussion 272-3.
3. Farrar, D.J., *Development of a prosthetic coronary artery bypass graft*. Heart Surg Forum, 2000. **3**(1): p. 36-40.
4. Tatoulis, J., et al., *The radial artery in coronary surgery: a 5-year experience--clinical and angiographic results*. Ann Thorac Surg, 2002. **73**(1): p. 143-7; discussion 147-8.
5. Ronan, J.W., et al., *Radial artery harvest: comparison of ultrasonic dissection with standard technique*. Ann Thorac Surg, 2000. **69**(1): p. 113-4.
6. Matsuura, A., et al., *Transplantation of the en bloc vascular system for coronary revascularization*. J Thorac Cardiovasc Surg, 2001. **121**(3): p. 520-5.
7. Lamm, P., et al., *Autologous endothelialized vein allograft: a solution in the search for small-caliber grafts in coronary artery bypass graft operations*. Circulation, 2001. **104**(12 Suppl 1): p. I108-14.
8. Da Lio, A.L. and N.F. Jones, *New concepts and materials in microvascular grafting: prosthetic graft endothelial cell seeding and gene therapy*. Microsurgery, 1998. **18**(4): p. 263-6.
9. Teebken, O.E. and A. Haverich, *Tissue engineering of small diameter vascular grafts*. Eur J Vasc Endovasc Surg, 2002. **23**(6): p. 475-85.
10. Llorens, S., J. Jordan, and E. Nava, *The nitric oxide pathway in the cardiovascular system*. J Physiol Biochem, 2002. **58**(3): p. 179-88.
11. Gonzalez, M.A. and A.P. Selwyn, *Endothelial function, inflammation, and prognosis in cardiovascular disease*. Am J Med, 2003. **115 Suppl 8A**: p. 99S-106S.
12. Pearson, J.D., *Endothelial cell function and thrombosis*. Baillieres Best Pract Res Clin Haematol, 1999. **12**(3): p. 329-41.
13. Biedermann, B.C., *Vascular endothelium: checkpoint for inflammation and immunity*. News Physiol Sci, 2001. **16**: p. 84-8.
14. Repo, H. and J.M. Harlan, *Mechanisms and consequences of phagocyte adhesion to endothelium*. Ann Med, 1999. **31**(3): p. 156-65.
15. Pober, J.S., *Immunobiology of human vascular endothelium*. Immunol Res, 1999. **19**(2-3): p. 225-32.
16. Pober, J.S., *Activation and injury of endothelial cells by cytokines*. Pathol Biol (Paris), 1998. **46**(3): p. 159-63.
17. Pober, J.S., *Endothelial activation: intracellular signaling pathways*. Arthritis Res, 2002. **4 Suppl 3**: p. S109-16.
18. Rademacher, A., et al., *Endothelialization of PTFE vascular grafts under flow induces significant cell changes*. Int J Artif Organs, 2001. **24**(4): p. 235-42.
19. Zilla, P., U. von Oppell, and M. Deutsch, *The endothelium: a key to the future*. J Card Surg, 1993. **8**(1): p. 32-60.
20. Zilla, P., M. Deutsch, and J. Meinhart, *Endothelial cell transplantation*. Semin Vasc Surg, 1999. **12**(1): p. 52-63.
21. Deutsch, M., et al., *[In vitro endothelialization of ePTFE vascular prostheses in clinical use: preliminary results]*. Vasa Suppl, 1990. **30**: p. 219-20.
22. Laube, H.R., et al., *Clinical experience with autologous endothelial cell-seeded*

- polytetrafluoroethylene coronary artery bypass grafts*. J Thorac Cardiovasc Surg, 2000. **120**(1): p. 134-41.
23. Kumar, T.R. and L.K. Krishnan, *A stable matrix for generation of tissue-engineered nonthrombogenic vascular grafts*. Tissue Eng, 2002. **8**(5): p. 763-70.
 24. Nerem, R.M. and A.E. Ensley, *The tissue engineering of blood vessels and the heart*. Am J Transplant, 2004. **4 Suppl 6**: p. 36-42.
 25. Meinhart, J.G., et al., *Clinical autologous in vitro endothelialization of 153 infrainguinal ePTFE grafts*. Ann Thorac Surg, 2001. **71**(5 Suppl): p. S327-31.
 26. Meinhart, J., M. Deutsch, and P. Zilla, *Eight years of clinical endothelial cell transplantation. Closing the gap between prosthetic grafts and vein grafts*. Asaio J, 1997. **43**(5): p. M515-21.
 27. Deutsch, M., et al., *Clinical autologous in vitro endothelialization of infrainguinal ePTFE grafts in 100 patients: a 9-year experience*. Surgery, 1999. **126**(5): p. 847-55.
 28. Jaffe, E.A., et al., *Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria*. J Clin Invest, 1973. **52**(11): p. 2745-56.
 29. Dengler, T.J. and J.S. Pober, *Cellular and molecular biology of cardiac transplant rejection*. J Nucl Cardiol, 2000. **7**(6): p. 669-85.
 30. Pober, J.S., et al., *Can graft endothelial cells initiate a host anti-graft immune response?* Transplantation, 1996. **61**(3): p. 343-9.
 31. Le Moine, A., M. Goldman, and D. Abramowicz, *Multiple pathways to allograft rejection*. Transplantation, 2002. **73**(9): p. 1373-81.
 32. Libby, P. and J.S. Pober, *Chronic rejection*. Immunity, 2001. **14**(4): p. 387-97.
 33. Hernandez-Fuentes, M.P., R.J. Baker, and R.I. Lechler, *The alloresponse*. Rev Immunogenet, 1999. **1**(3): p. 282-96.
 34. Vella, J.P., et al., *Cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides*. Transplantation, 1999. **67**(12): p. 1523-32.
 35. Valujskikh, A. and P.S. Heeger, *Emerging roles of endothelial cells in transplant rejection*. Curr Opin Immunol, 2003. **15**(5): p. 493-8.
 36. Kreisel, D., et al., *Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition*. Nat Med, 2002. **8**(3): p. 233-9.
 37. Epperson, D.E. and J.S. Pober, *Antigen-presenting function of human endothelial cells. Direct activation of resting CD8 T cells*. J Immunol, 1994. **153**(12): p. 5402-12.
 38. Baldwin, W.M., H. Ota, and E.R. Rodriguez, *Complement in transplant rejection: diagnostic and mechanistic considerations*. Springer Semin Immunopathol, 2003. **25**(2): p. 181-97.
 39. Hernandez-Fuentes, M.P. and R.I. Lechler, *Chronic graft loss. Immunological and non-immunological factors*. Contrib Nephrol, 2005. **146**: p. 54-64.
 40. Illigens, B.M., et al., *The relative contribution of direct and indirect antigen recognition pathways to the alloresponse and graft rejection depends upon the nature of the transplant*. Hum Immunol, 2002. **63**(10): p. 912-25.
 41. Bjorkman, P.J. and P. Parham, *Structure, function, and diversity of class I major histocompatibility complex molecules*. Annu Rev Biochem, 1990. **59**: p. 253-88.
 42. Fruh, K. and Y. Yang, *Antigen presentation by MHC class I and its regulation by interferon gamma*. Curr Opin Immunol, 1999. **11**(1): p. 76-81.
 43. Ma, W., et al., *Interferon-gamma rapidly increases peptide transporter (TAP) subunit expression and peptide transport capacity in endothelial cells*. J Biol Chem, 1997. **272**(26): p. 16585-90.
 44. Uebel, S. and R. Tampe, *Specificity of the proteasome and the TAP transporter*.

- Curr Opin Immunol, 1999. **11**(2): p. 203-8.
45. Krupnick, A.S., et al., *Mechanism of T cell-mediated endothelial apoptosis*. Transplantation, 2002. **74**(6): p. 871-6.
 46. Marelli-Berg, F.M. and S.J. Jarmin, *Antigen presentation by the endothelium: a green light for antigen-specific T cell trafficking?* Immunol Lett, 2004. **93**(2-3): p. 109-13.
 47. Pober, J.S., M.S. Kluger, and J.S. Schechner, *Human endothelial cell presentation of antigen and the homing of memory/effector T cells to skin*. Ann N Y Acad Sci, 2001. **941**: p. 12-25.
 48. Kreisel, D., et al., *Mouse vascular endothelium activates CD8+ T lymphocytes in a B7-dependent fashion*. J Immunol, 2002. **169**(11): p. 6154-61.
 49. Rogers, N.J. and R.I. Lechler, *Allorecognition*. Am J Transplant, 2001. **1**(2): p. 97-102.
 50. Derhaag, J.G., et al., *Effects of antibody reactivity to major histocompatibility complex (MHC) and non-MHC alloantigens on graft endothelial cells in heart allograft rejection*. Transplantation, 2000. **69**(9): p. 1899-906.
 51. Barshes, N.R., S.E. Goodpastor, and J.A. Goss, *Pharmacologic immunosuppression*. Front Biosci, 2004. **9**: p. 411-20.
 52. Krotz, F., et al., *Magnetofection potentiates gene delivery to cultured endothelial cells*. J Vasc Res, 2003. **40**(5): p. 425-34.
 53. Mann, M.J., et al., *Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial*. Lancet, 1999. **354**(9189): p. 1493-8.
 54. Furukawa, L., et al., *Adenoviral-mediated gene transfer of ICP47 inhibits major histocompatibility complex class I expression on vascular cells in vitro*. J Vasc Surg, 2000. **31**(3): p. 558-66.
 55. Freland, S., et al., *Rejection of allogeneic and syngeneic but not MHC class I-deficient tumor grafts by MHC class I-deficient mice*. J Immunol, 1998. **160**(2): p. 572-9.
 56. Schechner, J.S., et al., *In vivo formation of complex microvessels lined by human endothelial cells in an immunodeficient mouse*. Proc Natl Acad Sci U S A, 2000. **97**(16): p. 9191-6.
 57. Hultman, C.S., et al., *Immunogenicity of cultured keratinocyte allografts deficient in major histocompatibility complex antigens*. J Trauma, 1998. **45**(1): p. 25-33; discussion 33-4.
 58. Chefalo, P.J., et al., *Tapasin^{-/-} and TAP1^{-/-} macrophages are deficient in vacuolar alternate class I MHC (MHC-I) processing due to decreased MHC-I stability at phagolysosomal pH*. J Immunol, 2003. **170**(12): p. 5825-33.
 59. Ljunggren, H.G., et al., *MHC class I expression and CD8+ T cell development in TAP1/beta 2-microglobulin double mutant mice*. Int Immunol, 1995. **7**(6): p. 975-84.
 60. Fruh, K., et al., *A comparison of viral immune escape strategies targeting the MHC class I assembly pathway*. Immunol Rev, 1999. **168**: p. 157-66.
 61. Lichtenstein, D.L., et al., *Functions and mechanisms of action of the adenovirus E3 proteins*. Int Rev Immunol, 2004. **23**(1-2): p. 75-111.
 62. Signas, C., et al., *An adenovirus glycoprotein binds heavy chains of class I transplantation antigens from man and mouse*. Nature, 1982. **299**(5879): p. 175-8.
 63. Andersson, M., et al., *Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance*. Cell, 1985. **43**(1): p. 215-22.
 64. Jones, T.R., et al., *Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains*. Proc Natl Acad Sci U S

- A, 1996. **93**(21): p. 11327-33.
65. Chevalier, M.S. and D.C. Johnson, *Human cytomegalovirus US3 chimeras containing US2 cytosolic residues acquire major histocompatibility class I and II protein degradation properties*. J Virol, 2003. **77**(8): p. 4731-8.
 66. Ahn, K., et al., *Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47*. Embo J, 1996. **15**(13): p. 3247-55.
 67. Lehner, P.J., et al., *The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation*. Proc Natl Acad Sci U S A, 1997. **94**(13): p. 6904-9.
 68. Ahn, K., et al., *The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP*. Immunity, 1997. **6**(5): p. 613-21.
 69. Hengel, H., et al., *A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter*. Immunity, 1997. **6**(5): p. 623-32.
 70. Bauer, D. and R. Tampe, *Herpes viral proteins blocking the transporter associated with antigen processing TAP--from genes to function and structure*. Curr Top Microbiol Immunol, 2002. **269**: p. 87-99.
 71. Boname, J.M., et al., *Viral degradation of the MHC class I peptide loading complex*. Immunity, 2004. **20**(3): p. 305-17.
 72. Stevenson, P.G., et al., *Inhibition of MHC class I-restricted antigen presentation by gamma 2-herpesviruses*. Proc Natl Acad Sci U S A, 2000. **97**(15): p. 8455-60.
 73. Marasco, W.A. and S. Dana Jones, *Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression*. Adv Drug Deliv Rev, 1998. **31**(1-2): p. 153-170.
 74. Biocca, S., M.S. Neuberger, and A. Cattaneo, *Expression and targeting of intracellular antibodies in mammalian cells*. Embo J, 1990. **9**(1): p. 101-8.
 75. Chen, S.Y., J. Bagley, and W.A. Marasco, *Intracellular antibodies as a new class of therapeutic molecules for gene therapy*. Hum Gene Ther, 1994. **5**(5): p. 595-601.
 76. Huston, J.S., et al., *Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli*. Proc Natl Acad Sci U S A, 1988. **85**(16): p. 5879-83.
 77. Jackson, M.R., T. Nilsson, and P.A. Peterson, *Identification of a consensus motif for retention of transmembrane proteins in the endoplasmic reticulum*. Embo J, 1990. **9**(10): p. 3153-62.
 78. Kontermann, R.E., *Intrabodies as therapeutic agents*. Methods, 2004. **34**(2): p. 163-70.
 79. Lobato, M.N. and T.H. Rabbitts, *Intracellular antibodies as specific reagents for functional ablation: future therapeutic molecules*. Curr Mol Med, 2004. **4**(5): p. 519-28.
 80. Greenman, J., et al., *The use of intracellular single-chain antibody fragments to inhibit specifically the expression of cell surface molecules*. J Immunol Methods, 1996. **194**(2): p. 169-80.
 81. Jannot, C.B., et al., *Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells*. Oncogene, 1996. **13**(2): p. 275-82.
 82. Yuan, Q., et al., *Intracellular single-chain antibody inhibits integrin VLA-4 maturation and function*. Biochem J, 1996. **318** (Pt 2): p. 591-6.
 83. Hyland, S., et al., *Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor*. Oncogene, 2003. **22**(10): p. 1557-67.
 84. Beerli, R.R., W. Wels, and N.E. Hynes, *Intracellular expression of single chain antibodies reverts ErbB-2 transformation*. J Biol Chem, 1994. **269**(39): p. 23931-6.

85. Mhashilkar, A.M., et al., *Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies*. Hum Gene Ther, 1999. **10**(9): p. 1453-67.
86. Mhashilkar, A.M., et al., *Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies*. Embo J, 1995. **14**(7): p. 1542-51.
87. Marasco, W.A., W.A. Haseltine, and S.Y. Chen, *Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody*. Proc Natl Acad Sci U S A, 1993. **90**(16): p. 7889-93.
88. Bai, J., et al., *Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies*. J Biol Chem, 2003. **278**(3): p. 1433-42.
89. Herschhorn, A., A. Admon, and A. Hizi, *Recombinant human antibodies against the reverse transcriptase of human immunodeficiency virus type-1*. Biochim Biophys Acta, 2003. **1648**(1-2): p. 154-63.
90. Jendreyko, N., et al., *Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors*. J Biol Chem, 2003. **278**(48): p. 47812-9.
91. Tanaka, T., M.N. Lobato, and T.H. Rabbitts, *Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies*. J Mol Biol, 2003. **331**(5): p. 1109-20.
92. Auf der Maur, A., D. Escher, and A. Barberis, *Antigen-independent selection of stable intracellular single-chain antibodies*. FEBS Lett, 2001. **508**(3): p. 407-12.
93. Lobato, M.N. and T.H. Rabbitts, *Intracellular antibodies and challenges facing their use as therapeutic agents*. Trends Mol Med, 2003. **9**(9): p. 390-6.
94. Mhashilkar, A.M., et al., *Intrabody-mediated phenotypic knockout of major histocompatibility complex class I expression in human and monkey cell lines and in primary human keratinocytes*. Gene Ther, 2002. **9**(5): p. 307-19.
95. Doebeis, C., et al., *Efficient in vitro transduction of epithelial cells and keratinocytes with improved adenoviral gene transfer for the application in skin tissue engineering*. Transpl Immunol, 2002. **9**(2-4): p. 323-9.
96. Kolls, J., et al., *Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer*. Proc Natl Acad Sci U S A, 1994. **91**(1): p. 215-9.
97. Dengler, T.J. and J.S. Pober, *Human vascular endothelial cells stimulate memory but not naive CD8+ T cells to differentiate into CTL retaining an early activation phenotype*. J Immunol, 2000. **164**(10): p. 5146-55.
98. Dengler, T.J., D.R. Johnson, and J.S. Pober, *Human vascular endothelial cells stimulate a lower frequency of alloreactive CD8+ pre-CTL and induce less clonal expansion than matching B lymphoblastoid cells: development of a novel limiting dilution analysis method based on CFSE labeling of lymphocytes*. J Immunol, 2001. **166**(6): p. 3846-54.
99. Marelli-Berg, F.M., et al., *Lack of T cell proliferation without induction of nonresponsiveness after antigen presentation by endothelial cells*. Transplantation, 1999. **68**(2): p. 280-7.
100. Pober, J.S., et al., *Vascular cells have limited capacities to activate and differentiate T cells: implications for transplant vascular sclerosis*. Transpl Immunol, 1997. **5**(4): p. 251-4.
101. Biedermann, B.C. and J.S. Pober, *Human vascular endothelial cells favor clonal expansion of unusual alloreactive CTL*. J Immunol, 1999. **162**(12): p. 7022-30.
102. Zheng, L., et al., *Cytoprotection of human umbilical vein endothelial cells against apoptosis and CTL-mediated lysis provided by caspase-resistant Bcl-2 without*

- alterations in growth or activation responses.* J Immunol, 2000. **164**(9): p. 4665-71.
103. Biedermann, B.C. and J.S. Pober, *Human endothelial cells induce and regulate cytolytic T cell differentiation.* J Immunol, 1998. **161**(9): p. 4679-87.
 104. Seifert, M., et al., *Generation and characterization of a human monoclonal IgM antibody that recognizes a conserved epitope shared by lipopolysaccharides of different gram-negative bacteria.* Hybridoma, 1996. **15**(3): p. 191-8.
 105. Symington, F.W. and E.B. Santos, *Recognition of keratinocytes by cytotoxic T cells specific for conventional HLA class-I alloantigen.* J Invest Dermatol, 1990. **95**(2): p. 224-8.
 106. Roden, M.M., et al., *A novel cytolysis assay using fluorescent labeling and quantitative fluorescent scanning technology.* J Immunol Methods, 1999. **226**(1-2): p. 29-41.
 107. Lorber, M.I., et al., *Human allogeneic vascular rejection after arterial transplantation and peripheral lymphoid reconstitution in severe combined immunodeficient mice.* Transplantation, 1999. **67**(6): p. 897-903.
 108. Rogers, I. and R.F. Casper, *Stem cells: you can't tell a cell by its cover.* Hum Reprod Update, 2003. **9**(1): p. 25-33.
 109. Cohen, Y. and A. Nagler, *Cord blood biology and transplantation.* Isr Med Assoc J, 2004. **6**(1): p. 39-46.
 110. Rogers, I., et al., *Human UC-blood banking: impact of blood volume, cell separation and cryopreservation on leukocyte and CD34(+) cell recovery.* Cytotherapy, 2001. **3**(4): p. 269-76.
 111. St George, J.A., *Gene therapy progress and prospects: adenoviral vectors.* Gene Ther, 2003. **10**(14): p. 1135-41.
 112. Jooss, K. and N. Chirmule, *Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.* Gene Ther, 2003. **10**(11): p. 955-63.
 113. Amalfitano, A., *Utilization of adenovirus vectors for multiple gene transfer applications.* Methods, 2004. **33**(2): p. 173-8.
 114. Martinet, W., D.M. Schrijvers, and M.M. Kockx, *Nucleofection as an efficient nonviral transfection method for human monocytic cells.* Biotechnol Lett, 2003. **25**(13): p. 1025-9.
 115. Qian, H.S., et al., *Improved adenoviral vector for vascular gene therapy : beneficial effects on vascular function and inflammation.* Circ Res, 2001. **88**(9): p. 911-7.
 116. Amalfitano, A., *Use of multiply deleted adenovirus vectors to probe adenovirus vector performance and toxicities.* Curr Opin Mol Ther, 2003. **5**(4): p. 362-6.
 117. Nicklin, S.A., et al., *In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors.* J Gene Med, 2004. **6**(3): p. 300-8.
 118. Lilley, B.N. and H.L. Ploegh, *A membrane protein required for dislocation of misfolded proteins from the ER.* Nature, 2004. **429**(6994): p. 834-40.
 119. Wedgwood, J.F., L. Hatam, and V.R. Bonagura, *Effect of interferon-gamma and tumor necrosis factor on the expression of class I and class II major histocompatibility molecules by cultured human umbilical vein endothelial cells.* Cell Immunol, 1988. **111**(1): p. 1-9.
 120. Muruve, D.A., *The innate immune response to adenovirus vectors.* Hum Gene Ther, 2004. **15**(12): p. 1157-66.
 121. Channon, K.M., et al., *Acute host-mediated endothelial injury after adenoviral gene transfer in normal rabbit arteries: impact on transgene expression and endothelial function.* Circ Res, 1998. **82**(12): p. 1253-62.
 122. Gumperz, J.E. and P. Parham, *The enigma of the natural killer cell.* Nature, 1995. **378**(6554): p. 245-8.
 123. Correa, I., L. Corral, and D.H. Raulet, *Multiple natural killer cell-activating signals*

- are inhibited by major histocompatibility complex class I expression in target cells. *Eur J Immunol*, 1994. **24**(6): p. 1323-31.
124. Raulet, D.H., et al., *Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors*. *Immunol Rev*, 1997. **155**: p. 41-52.
 125. Itescu, S., et al., *Lysis of pig endothelium by IL-2 activated human natural killer cells is inhibited by swine and human major histocompatibility complex (MHC) class I gene products*. *Ann Transplant*, 1997. **2**(1): p. 14-20.
 126. Zimmer, J., et al., *Inefficient protection of human TAP-deficient fibroblasts from autologous NK cell-mediated lysis by cytokines inducing HLA class I expression*. *Eur J Immunol*, 1999. **29**(4): p. 1286-91.
 127. Pazmany, L., et al., *Protection from natural killer cell-mediated lysis by HLA-G expression on target cells*. *Science*, 1996. **274**(5288): p. 792-5.
 128. Pober, J.S., et al., *Immunopathology of human T cell responses to skin, artery and endothelial cell grafts in the human peripheral blood lymphocyte/severe combined immunodeficient mouse*. *Springer Semin Immunopathol*, 2003. **25**(2): p. 167-80.